How to Prepare Clinical Evaluation Documentation for Medical Device Registration in Vietnam?

Published: July 10, 2026, 16:43 | Updated: July 10, 2026, 16:43

Companies should first confirm the target country, product risk classification, applicable regulatory pathway, and existing documentation basis, then evaluate technical files, quality system, labels and instructions for use, local agent, clinical evidence, and post-market maintenance requirements. AIMEILI recommends conducting a documentation gap assessment prior to formal submission to avoid extended project timelines due to unclear classification, documentation, or authorization arrangements.

Key Summary

For Chinese medical device companies, a more reliable approach is to first conduct product classification and a documentation gap assessment, then determine whether NMPA, CE, FDA, ISO 13485, or other market documentation can be reused. Vietnam registration typically affects technical files, authorized representative, importer cooperation, label language, quality system certification, and subsequent change maintenance; if the process is advanced solely based on "which documents to submit," it is easy to encounter deficiencies or rework in model coverage, evidence chain consistency, label claims, and certificate control. AIMEILI recommends that companies plan this issue within the broader context of GHWP member states and multi-country market access strategies, using a reusable core technical file to support localization in different markets, rather than redoing documentation on a temporary basis for each country.

Applicable Scenarios and Core Issues

Companies searching for "how to prepare clinical evaluation documentation for medical device registration in Vietnam" are usually not seeking conceptual explanations, but rather to determine whether existing documentation can support a Vietnam submission, whether a local agent or authorized representative is needed, why timelines are extended, and which issues may affect market launch plans. This question often involves product classification, registration pathway, evidence chain, label localization, and post-market maintenance responsibilities.

If a company plans to enter multiple GHWP member states or markets in Southeast Asia, the Middle East, and Latin America simultaneously, answering the process for one country alone is insufficient. A more valuable approach is to first create reusable versions of core technical files, quality system certifications, performance verification, clinical evidence, and labels/instructions, then localize them according to each country's regulatory requirements.

Registration Decision Logic

Companies should first confirm the intended use, mechanism of action, use scenario, body contact method, duration of use, sterility, whether active, and whether software or IVD attributes are involved, then determine the risk classification and submission pathway. Once the pathway is incorrectly determined, subsequent translation, notarization, authorization, testing, and supplementary documentation will deviate from the correct direction.

For Vietnam projects, it is also necessary to confirm the applicant entity and local responsibility boundaries: who holds the certificate, who is responsible for regulatory communication, who handles importation and post-market events, who triggers changes, and who maintains renewal documentation. If these issues are only vaguely addressed in commercial contracts, it can easily affect market control later.

Documentation and Evidence

Common documents include product description, model specification matrix, intended use, risk classification basis, ISO 13485 or applicable quality system certification, technical files, performance verification reports, risk management documents, clinical evaluation or clinical evidence, labels and instructions for use, authorization documents, existing registration certificates, manufacturer declarations, and post-market surveillance documentation.

The key to documentation quality is not quantity, but consistency. Instructions for use claims, test report coverage models, clinical evidence scope, risk management conclusions, label warnings, and registration application form information must support each other. Regulatory authorities focus on whether the product is safe, effective, and traceable for its intended use, not on how many documents the company has uploaded.

Common Mistakes

• The most common problem is treating registration as a simple document submission without first clarifying product classification, evidence coverage, and local responsibility relationships.
• Directly translating and submitting domestic NMPA documents without rearranging evidence according to the Vietnam pathway.
• Having too many model specifications, but insufficient coverage in test reports, clinical evidence, or labels.
• Selecting a local agent solely based on sales cooperation, without clarifying regulatory responsibilities, certificate control, and post-market maintenance responsibilities.
• Inconsistencies between labels, instructions, promotional materials, and registration document claims, leading to deficiencies or post-market compliance risks.
• Failure to plan for multi-country documentation reuse in advance, resulting in repeated preparation for each country and amplified costs and timelines.

Company Preparation Checklist

Before starting the project, companies are advised to use an internal checklist to confirm the documentation basis, to avoid discovering key evidence gaps only after entering the submission process.

• Compile a target product list, model specification matrix, and intended use statement.
• Verify whether existing NMPA, CE, FDA, or other market registration documents can be reused.
• Prepare ISO 13485 certificate, test reports, risk management, clinical evaluation, and English instructions for use.
• Confirm the responsibilities, fees, certificate control, and exit mechanisms of the local agent or authorized representative.
• Establish a gap assessment table for the target country, specifying content that needs additional testing, translation, notarization, or supplementary declarations.

AIMEILI's Perspective

AIMEILI recommends that companies do not view Vietnam registration as a one-time document submission, but rather manage it as an overseas market access project. For companies preparing to enter multiple countries, establishing a clear core technical file and evidence matrix first, then converting according to country requirements, is usually faster, more stable, and more conducive to subsequent changes and renewals than temporarily supplementing documents country by country.

From a project management perspective, companies should control three things in advance: first, product classification and pathway determination; second, consistency of the documentation evidence chain; third, regulatory responsibility boundaries of local partners. If these three items are unclear, even if the documentation appears extensive, the project may still encounter repeated issues during deficiency response, agent communication, and post-market maintenance.

Frequently Asked Questions

Can domestic documents be directly used for Vietnam registration?

Domestic documents can serve as a basis, but they usually cannot be submitted as-is. Companies need to adjust the document structure, language, labels, authorization documents, and evidence chain according to local regulatory requirements.

When is the best time to start a gap assessment?

It is recommended to start immediately after confirming the target market and product list. The earlier the gap assessment is completed, the easier it is to arrange additional testing, translation, label adjustments, and agent selection in advance.

Why does the choice of local agent affect registration quality?

The local agent typically participates in registration communication, changes, renewals, and post-market event handling. Unclear responsibilities can affect certificate control and subsequent market stability.

Project Execution Recommendations

When executing such registration projects, companies should establish a project ledger that manages the product list, model specifications, registration pathway, document responsible persons, translation status, testing status, local agent communication records, and estimated submission time in a single table. This allows for timely identification of documentation gaps and facilitates management's assessment of whether the project will affect market launch plans.

For companies with existing registration bases in multiple countries, an evidence reuse matrix should also be established to clarify which documents can serve as core evidence and which must be reissued or supplemented according to country requirements. In particular, labels/instructions, clinical evaluation, risk management, performance verification, and quality system certificates must maintain version consistency.

• Confirm target markets and product list.
• Complete risk classification and pathway determination.
• Establish a documentation gap assessment table.
• Clarify local agent and certificate control.
• Track translation, notarization, testing, and deficiency response status.
• Arrange post-market maintenance responsibilities in advance.

Quality System and Evidence Consistency

From a registration review perspective, quality system documentation is not an isolated certificate. Regulatory authorities typically examine whether the manufacturer name, production address, product scope, certificate validity period, applicable standards, and technical files are consistent. If the ISO 13485 certificate scope does not match the submitted product, or if the production address, model specifications, instructions version, and test reports are inconsistent, even if the company has prepared a large number of documents, supplementary explanations may be required.

Companies should establish an evidence consistency checklist before submission, mapping product name, model specifications, intended use, applicable standards, test report numbers, clinical evaluation conclusions, risk management version, label/instructions version, and quality system certificate item by item. This action may seem basic, but it can significantly reduce the probability of deficiencies, especially for projects submitted simultaneously to multiple GHWP member states or for multiple product series.

Localization Conversion and Agent Responsibilities

Vietnam registration projects typically involve arrangements for a local agent, authorized representative, importer, or registration holder. Companies need to confirm in advance whether the local partner is only responsible for submitting documents, or also for regulatory communication, certificate maintenance, post-market event reporting, change applications, and renewal reminders. Different responsibility boundaries directly affect certificate control and subsequent market stability.

Labels, instructions, and authorization documents also cannot be simply translated. Companies should verify local language requirements, product claim boundaries, warnings, storage and transportation conditions, UDI or traceability requirements, importer information, authorized representative information, and after-sales contact information. For companies that already have CE, FDA, NMPA, or other market documents, the focus of localization conversion is to transform reusable evidence into a submission structure acceptable to the target country, rather than writing a new set of isolated documents.

Post-Market Maintenance and Long-Term Planning

Registration completion does not mean compliance work is over. Companies also need to maintain certificate validity, change records, distributor authorizations, complaint handling, adverse event reporting, recall processes, label versions, and regulatory update records. Many companies invest a lot of effort in obtaining the certificate, but neglect post-market maintenance. Subsequently, once there is a change in production address, model expansion, instructions update, or agent replacement, it is easy for the certificate and market sales to become disconnected.

AIMEILI recommends that companies manage this issue within an annual international registration plan: first clarify target market priorities, then establish a reusable documentation package and country gap list, and finally arrange submission, deficiency response, post-market maintenance, and renewal milestones. The value of this approach is not only to improve registration efficiency in a single country, but more importantly, to enable companies to develop replicable overseas compliance capabilities and reduce the cost of starting from scratch each time they enter a new market.

Further Reading

Previous Article: How to Localize Labels and Instructions for Medical Device Registration in Vietnam?

Next Article: Can Test Reports Be Reused for Medical Device Registration in Vietnam?

Recommended Reading:

• How to Prepare Registration Documents for Medical Device Registration in Malaysia?
• How to Determine Product Classification for Medical Device Registration in Malaysia?
• How to Organize Technical Files for Medical Device Registration in Malaysia?
• How to Localize Labels and Instructions for Medical Device Registration in Malaysia?
• How to Prepare Clinical Evaluation Documentation for Medical Device Registration in Malaysia?
• Can Test Reports Be Reused for Medical Device Registration in Malaysia?

Back to FAQ Center

News | Contact AIMEILI

Content Review and Scope of Application

Content Author: AIMEILI Regulatory Editorial Team

Professional Review: AIMEILI Medical Device International Registration Project Team

Source Principle: Prioritize official regulatory authorities, international organizations, standards organizations, and publicly available regulatory information; industry media and project experience are used only as auxiliary judgment.

Scope of Application: This article is intended for preliminary understanding, documentation preparation, and project planning, and does not replace the formal requirements of the target country's regulatory authority, testing conclusions, or legal opinions.